Which are the companies that offer hantavirus tests to clinical laboratories?

Hantavirus testing in the U.S. remains a small but strategically important niche within the broader infectious disease diagnostics market—supported by a concentrated set of kit manufacturers and high complexity reference labs. Companies such as Calbiotech, Biofargo, Creative Diagnostics, Quest Diagnostics, Mayo Clinic Laboratories, and ARUP anchor the ecosystem across ELISA, RT PCR, and rapid lateral flow formats.

The microbiology segment illustrates a familiar pattern in emerging‑pathogen markets: low test volumes, high clinical acuity, limited competition, and meaningful differentiation in assay performance and regulatory positioning. Molecular RT-PCR solutions target early-phase detection, while ELISA-based IgM/IgG testing continues to dominate reimbursable clinical workflows. Rapid tests are expanding distribution but still require confirmatory lab testing—creating layered revenue opportunities across formats.

As infectious disease portfolios are reassessed post COVID, niche pathogens like hantavirus offer signals about where innovation, consolidation, and strategic partnerships may emerge next—especially in molecular menu expansion, specialty reference testing, and global surveillance markets. GRN IVD Consulting supports investors, diagnostics leaders, and corporate development teams with market sizing, competitive mapping, assay benchmarking, and strategic diligence across the IVD landscape, including specialized segments such as hantavirus. If your team is evaluating opportunities in infectious disease diagnostics or adjacent markets, let’s connect at grnivdconsulting@gmail.com